China Accepts First Line HER2 ADC Filing
China-originated regulatory signal: Hengrui disclosed on 29 October that NMPA accepted and placed its rezetecan trastuzumab application into priority review for first-line locally advanced or metastatic HER2-positive breast cancer, with or without pertuzumab. This…
